Achilles Therapeutics logo

Achilles TherapeuticsNASDAQ: ACHL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

31 March 2021

Next earnings report:

04 April 2025

Last dividends:

N/A

Next dividends:

N/A
$41.09 M
-81%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:31:00 GMT
$1.00-$0.03(-2.91%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ACHL Latest News

Achilles Therapeutics Reports Third Quarter 2024 Financial Results
globenewswire.com14 November 2024 Sentiment: POSITIVE

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –

Achilles Therapeutics to Present at Upcoming Conferences
GlobeNewsWire12 June 2023 Sentiment: NEGATIVE

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:

3 Stocks With 1,000% Upside Potential
InvestorPlace21 May 2023 Sentiment: POSITIVE

If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.

What type of business is Achilles Therapeutics?

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

What sector is Achilles Therapeutics in?

Achilles Therapeutics is in the Healthcare sector

What industry is Achilles Therapeutics in?

Achilles Therapeutics is in the Biotechnology industry

What country is Achilles Therapeutics from?

Achilles Therapeutics is headquartered in United Kingdom

When did Achilles Therapeutics go public?

Achilles Therapeutics initial public offering (IPO) was on 31 March 2021

What is Achilles Therapeutics website?

https://www.achillestx.com

Is Achilles Therapeutics in the S&P 500?

No, Achilles Therapeutics is not included in the S&P 500 index

Is Achilles Therapeutics in the NASDAQ 100?

No, Achilles Therapeutics is not included in the NASDAQ 100 index

Is Achilles Therapeutics in the Dow Jones?

No, Achilles Therapeutics is not included in the Dow Jones index

When was Achilles Therapeutics the previous earnings report?

No data

When does Achilles Therapeutics earnings report?

The next expected earnings date for Achilles Therapeutics is 04 April 2025